Abstract: Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian cells, including cells of human origin, in vitro or in vivo. The inventive method involves the use of a composition containing a polynucleotide encoding a pituitary tumor transforming gene carboxy-terminal peptide (PTTG-C), which has the ability to regulate endogenous pituitary tumor transforming gene (PTTG) expression and/or function in a dominant negative manner. Kits comprising the inventive compositions are also disclosed for the treatment of neoplastic cellular proliferation in vitro or in vivo. Isolated polynucloetides encoding PTTG-C peptides.

Abstract: Disclosed are isolated antibodies that specifically bind a human pituitary tumor transforming gene carboxy-terminal peptide (PTTG-C).

Abstract: Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian cells, including cells of human origin, in vitro or in vivo. The inventive method involves the use of a composition containing a pituitary tumor transforming gene carboxy-terminal peptide (PTTG-C), which can be comprised in a chimeric protein, which has the ability to regulate endogenous pituitary tumor transforming gene (PTTG) expression and/or function in a dominant negative manner. Kits comprising the inventive compositions are also disclosed for the treatment of neoplastic cellular proliferation in vitro or in vivo. Isolated PTTG-C peptides and PTTG-C-containing chimeric proteins are described.

Abstract: Disclosed are isolated antibodies that specifically bind a murine pituitary tumor transforming gene carboxy-terminal peptide (PTTG-C).

Abstract: Disclosed are isolated antibodies that specifically bind a rat pituitary tumor transforming gene carboxy-terminal peptide (PTTG-C).

Abstract: Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian cells, including cells of human origin, in vitro or in vivo. The inventive method involves the delivery of polynucleotides antisense to PTTG-C-related polynucleotides to mammalian cells, whether in vitro or in vivo, to inhibit the endogenous expression of PTTG. Also disclosed are compositions comprising antisense PTTG carboxy-terminal-related polynucleotides, including compositions comprising expression vectors containing the PTTG-C-related polynucleotides. Kits comprising the inventive compositions are also disclosed for the treatment of neoplastic cellular proliferation in vitro or in vivo.

Abstract: Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian cells, including cells of human origin, in vitro or in vivo. The inventive method involves the delivery of polynucleotides antisense to PTTG-C-related polynucleotides to mammalian cells, whether in vitro or in vivo, to inhibit the endogenous expression of PTTG. Also disclosed are compositions comprising antisense PTTG carboxy-terminal-related polynucleotides, including compositions comprising expression vectors containing the PTTG-C-related polynucleotides.

Abstract: Disclosed is a non-human mammal comprising a cell that comprises an expression vector containing a promoter and a PTTG carboxy-terminal-related DNA.

Abstract: Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian cells, including cells of human origin, in vitro or in vivo. The inventive method involves the use of a composition containing a polynucleotide encoding a pituitary tumor transforming gene carboxy-terminal peptide (PTTG-C), which has the ability to regulate endogenous pituitary tumor transforming gene (PTTG) expression and/or function in a dominant negative manner. Kits comprising the inventive compositions are also disclosed for the treatment of neoplastic cellular proliferation in vitro or in vivo. Isolated polynucloetides encoding PTTG-C peptides.

Abstract: Disclosed is a non-human mammal comprising a cell that comprises an expression vector containing a promoter and a PTTG carboxy-terminal-related DNA.

Abstract: Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian cells, including cells of human origin, in vitro or in vivo. The inventive method involves the use of a composition containing a pituitary tumor transforming gene carboxy-terminal peptide (PTTG-C), which can be comprised in a chimeric protein, which has the ability to regulate endogenous pituitary tumor transforming gene (PTTG) expression and/or function in a dominant negative manner. Kits comprising the inventive compositions are also disclosed for the treatment of neoplastic cellular proliferation in vitro or in vivo. Isolated PTTG-C peptides and PTTG-C-containing chimeric proteins are described.

Abstract: Disclosed is a non-human mammal comprising a cell that comprises an expression vector containing a promoter and a PTTG carboxy-terminal-related DNA

Abstract: Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian cells, including cells of human origin, in vitro or in vivo. The inventive method involves the use of a composition containing a pituitary tumor transforming gene carboxy-terminal peptide (PTTG-C), which can be comprised in a chimeric protein, which has the ability to regulate endogenous pituitary tumor transforming gene (PTTG) expression and/or function in a dominant negative manner. Kits comprising the inventive compositions are also disclosed for the treatment of neoplastic cellular proliferation in vitro or in vivo. Isolated PTTG-C peptides and PTTG-C-containing chimeric proteins are described.

Abstract: Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian breast or ovarian cells, including cells of human origin, in vitro or in vivo. The inventive method involves the use of a pituitary tumor transforming gene carboxy-terminal peptide (PTTG-C), which has the ability to regulate endogenous pituitary tumor transforming gene (PTTG) expression and/or function in a dominant negative manner. In some embodiments, the invention is directed to gene-based treatments that deliver PTTG-C-related polynucleotides to mammalian cells, whether in vitro or in vivo, to inhibit the endogenous expression of PTTG. Other embodiments are directed to peptide-based treatments that deliver PTTG-C peptide molecules to the cells, which inhibit endogenous PTTG expression and/or PTTG function.

Abstract: Disclosed is a method of modulating angiogenesis in a tissue comprising mammalian cells, including cells of human origin, in vitro or in vivo. Also disclosed are a method of enhancing wound healing and/or tissue regeneration and a method of limiting scar formation.

Abstract: The nucleotide and deduced amino acid sequences of the four variable domains of the major outer membrane proteins of the 15 serovars of Chlamydia trachomatis are disclosed together with sequence and immunogenic analysis of these domains.

Abstract: Devices and methods for generating electrogenerated chemiluminescence, using an electrode which is coated with an immobilized layer of a compound capable of generating ECL. The coated electrode can be immersed along with a second electrode into an electrolyte solution containing a reactant which can react with the immobilized compound to generate ECL.

Abstract: The nucleotide and deduced amino acid sequences of the four variable domains of the major outer membrane proteins of the 15 serovars of Chlamydia trachomatis are disclosed together with sequence and immunogenic analysis of these domains.

Abstract: Devices and methods for generating electrogenerated chemiluminescence, using an electrode which is coated with an immobilized layer of a compound capable of generating ECL. The coated electrode can be immersed along with a second electrode into an electrolyte solution containing a reactant which can react with the immobilized compound to generate ECL.